Investor Presentaiton

BIOND BIOLOGICS Pipeline of first-in-class drug candidates Program Immuno-Oncology BND-22: ILT2 (LILRB1) anti-ILT2 blocking mAb BION-206: Soluble CD28 reduction Overcoming anti-PD-1 resistance by targeting CD28 shedding BND-35: ILT3 (LILRB4) anti-ILT3 blocking mAb INspire - Intracellular Delivery Platform BION-301: Intracellular Oncology Target Biologic agent targeting oncogenic cell signaling regulator Discovery Pre-Clinical Development IND enabling Studies Phase 1 Phase 1 on-going Biond Biologics Corporate Presentation | May 2021 | Non-confidential 6

View entire presentation